Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema

Pichi, Francesco

DOI: https://doi.org/10.1007/s10792-024-03226-2

IF: 2.029

2024-06-25

International Ophthalmology

Abstract:To assess the effectiveness of a switch to faricimab in individuals affected by DME and previously treated with aflibercept.

ophthalmology

What problem does this paper attempt to address?

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

Lorenzo Ferro Desideri,Carlo Enrico Traverso,Massimo Nicolò,Marion R. Munk

DOI: https://doi.org/10.3390/pharmaceutics15051413

IF: 6.525

2023-05-06

Pharmaceutics

Abstract:Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered the first-line therapeutic strategy for treating macular exudative diseases; including wet age-related macular degeneration (w-AMD) and diabetic macular edema (DME). Despite the important clinical achievements obtained by anti-VEGF drugs in the management of w-AMD and DME; some limits still remain; including high treatment burden; the presence of unsatisfactory results in a certain percentage of patients and long-term visual acuity decline due to complications such as macular atrophy and fibrosis. Targeting the angiopoietin/Tie (Ang/Tie) pathway beyond the VEGF pathway may be a possible therapeutic strategy; which may has the potential to solve some of the previous mentioned challenges. Faricimab is a new; bispecific antibody targeting both VEGF-A and the Ang-Tie/pathway. It was approved by FDA and; more recently; by EMA for treating w-AMD and DME. Results from phase III trials TENAYA and LUCERNE (w-AMD) and RHINE and YOSEMITE (DME) have shown the potential of faricimab to maintain clinical efficacy with more prolonged treatment regimens compared to aflibercept (12 or 16 weeks) with a a good safety profile.

pharmacology & pharmacy
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration

Aisha A Aldhanhani,Ola A Azzam,Sahar H AlAli,Khaled G Almasri,Shaikha H Aljneibi,Francesco Pichi

DOI: https://doi.org/10.1007/s10792-024-03297-1

2024-09-05

Abstract:Purpose: To investigate the efficacy and outcomes of switching neovascular age-related macular degeneration (nAMD) patients from aflibercept to faricimab, focusing on visual acuity, retinal fluid management, and treatment intervals. The primary aim was to assess the early outcomes in nAMD patients refractory to aflibercept and explore faricimab's potential as a longer-lasting therapeutic alternative. Methods: A single-center retrospective study was conducted on 50 refractory nAMD patients at Cleveland Clinic Abu Dhabi from September 2022-May 2023. Patients were switched from aflibercept to faricimab, having met specific criteria for refractory nAMD. The study analyzed best-corrected visual acuity (BCVA), central subfield thickness (CST), and fluid changes post-switch, using Optical Coherence Tomography (OCT). Results: After three faricimab injections, significant reductions in CST were observed, with a notable decrease in retinal fluid. The mean BCVA remained stable throughout the study period. Although there was a decrease in the maximum pigment epithelial detachment (PED) height, it was not statistically significant. Treatment intervals post-switch showed that the majority of patients maintained or extended their treatment intervals, with a significant proportion achieving resolution of intraretinal fluid (IRF) and subretinal fluid (SRF). Conclusions: Switching to faricimab from aflibercept in refractory nAMD patients led to significant improvements in retinal fluid management and CST, with stable BCVA outcomes. Faricimab presents a promising alternative for patients requiring frequent aflibercept injections, potentially offering a more manageable treatment regimen with extended dosing intervals. This study highlights the need for personalized therapeutic strategies in nAMD treatment, though further research is necessary to optimize treatment switches.
Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema

Asad Farooq Durrani,Bita Momenaei,Taku Wakabayashi,Sudheshna Vemula,Saagar A Pandit,Jason Hsu,Allen C Ho,Marc J Spirn,Michael A Klufas,Sunir J Garg,James F Vander,Carl D Regillo,Allen Chiang,Ajay E Kuriyan,Yoshihiro Yonekawa

DOI: https://doi.org/10.1136/bjo-2023-324394

2024-02-12

British Journal of Ophthalmology

Abstract:Background To assess the anatomical and functional outcomes in eyes with persistent diabetic macular oedema (pDME) on chronic anti-vascular endothelial growth factor therapy switched to intravitreal faricimab. Methods Patients with pDME on chronic anti-vascular endothelial growth factor therapy that were switched to faricimab and received at least three injections at our institution between April 2022 and May 2023 were included in this study. Patients were excluded if they had complete response to previous treatment but were switched to extend treatment intervals if they had steroid or laser treatment for DME within 6 months prior to switch. Clinical and imaging data were extracted from the electronic medical record. Central foveal thickness (CFT) and Snellen visual acuity (VA) were obtained before and after three intravitreal faricimab injections. Generalised estimating equations were used to analyse the change in CFT and VA. Result During the study period, 69 eyes of 53 patients met inclusion criteria. The mean age was 68.6±9.0 years. The mean number of injections prior to switch was 18.1±16.0. Pre-switch mean logarithm of the minimal angle of resolution VA was 0.40±0.30 (Snellen equivalent 20/50) and 0.38±0.27 (Snellen equivalent 20/48) after three faricimab injections (p=0.397). Mean CFT improved from 380±155 microns to 323±147 microns (p<0.001). No ophthalmic or systemic adverse events occurred during the study period. Conclusions Intravitreal faricimab can improve anatomic outcomes while maintaining visual acuity in eyes with pDME previously treated with anti-VEGF therapy.

ophthalmology
Comparative effect of intravitreal faricimab versus aflibercept in a patient with diabetic macular oedema

Javier Montero‐Moreno,Cecilia Diez‐Montero,Maria Eugenia Sanchis‐Merino,Rosario Hernandez‐Fernandez,Elisabeth Cañibano‐Perez

DOI: https://doi.org/10.1111/aos.15879

2024-01-01

Acta Ophthalmologica

Abstract:Aims/Purpose: To report the changes in diabetic macular oedema (DME) and visual acuity (VA) in a single patient with bilateral DME treated with intravitreal 2 mg aflibercept (AFL) and 6 mg faricimab (FAR) in the context of a randomized clinical trial during 44 weeks. Methods: Interventional case report within a clinical trial. Results: A 57‐year‐old female patient entered a clinical trial to test the efficacy of FAR for DME. DME was present in both eyes. The left eye (LE) was randomized to masked treatment (which resulted to be 6 consecutive intravitreal FAR every 4 weeks followed by FAR every 8 weeks, totalling 8 injections). The RE received open label treatment with monthly AFL at baseline; and then every 4 weeks after Week 16, until Week 44, totalling 8 injections). Baseline best corrected VA was RE 50 letters and LE 64 letters; at Week 24, RE 46 and LE 62; and at Week 44, RE 46 and LE 76. Optical coherence tomography (OCT) revealed a progressive reduction of central macular thickness (CMT) as well as hard exudates and disorganization of retinal layers in both eyes. Angio OCT showed a progression of non‐perfused macular areas in both eyes; the anti‐vascular endothelial growth factor effect of the treatment induced a reduction in the severity of diabetic retinopathy in both eyes demonstrated by fluorescein angiography and colour fundus imaging. Conclusions: Our results show that treatment with AFL and FAR in the eyes of the same patient may cause a similar reduction in CMT, even though a better visual outcome was observed in the eye treaded by FAR.

ophthalmology
Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration

Franziska Eckardt,Anna Lorger,Michael Hafner,Julian Elias Klaas,Benedikt Schworm,Thomas Christian Kreutzer,Siegfried Georg Priglinger,Jakob Siedlecki

DOI: https://doi.org/10.1038/s41598-024-59632-0

IF: 4.6

2024-04-27

Scientific Reports

Abstract:Aim of this study was to evaluate the efficacy of switching treatment to faricimab in neovascular age-related macular degeneration (nAMD) from other anti-VEGF agents. Fifty-eight eyes of fifty-one patients with nAMD and a full upload series of four faricimab injections were included. Demographic data, multimodal imaging and treatment parameters were recorded. The primary outcome measures were changes in central subfield thickness (CST) and subfoveal choroidal thickness (SFCT). A subgroup analysis was performed for eyes with prior ranibizumab (R) or aflibercept (A) treatment. Mean injection intervals before and after switching were comparable (33.8 ± 11.2 vs. 29.3 ± 2.6 days; p = 0.08). Mean CST of 361.4 ± 108.1 μm prior to switching decreased significantly to 318.3 ± 97.7 μm ( p < 0.01) after the third faricimab injection, regardless of prior anti-VEGF treatment ( p < 0.01). Although SFCT slightly improved for the whole cohort from 165.8 ± 76.8 μm to 161.0 ± 82,8 μm ( p = 0.029), subgroup analysis did not confirm this positive effect (subgroup R: p = 0.604; subgroup A: p = 0.306). In patients with a suboptimal response to aflibercept or ranibizumab in nAMD, farcimab can improve CST and slightly improve or maintain SFCT. Further prospective randomized trials are warranted.

multidisciplinary sciences
Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration

Benjamin Ng,Hema Kolli,Naduviledeth Ajith Kumar,Matthew Azzopardi,Abison Logeswaran,Julius Buensalido,Bushra Mushtaq,Randhir Chavan,Yu Jeat Chong

DOI: https://doi.org/10.3390/life14020193

2024-01-30

Life

Abstract:Faricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict these outcomes; and obtain patient subjective experience on this new injection. This is a retrospective case review with clinical and imaging data from a tertiary referral unit (Birmingham and Midland Eye Centre, UK), involving patients who were switched to faricimab between 1 January and 1 December 2023. In all, 63 eyes (54 patients) with a mean age of 79.2 ± 7.8 and mean of 41.5 ± 22.4 previous anti-VEGF injections were analysed. With a mean of 4.81 ± 1.16 faricimab injections over 6.98 ± 1.75 months, post-treatment visual acuity was logMAR 0.49 ± 0.36 and central macular thickness (CMT) was 320.3 ± 97.9 μm. After first dose, 39.1% achieved complete dryness and 89.1% had anatomical improvement. Presence of subretinal fluid was a predictor of better functional outcomes (p = 0.001, β = −0.182), while initial CMT predicted better anatomical outcomes (p = 0.001, β = 0.688). Compared to their experiences of previous anti-VEGF injections, 89% of patients reported no more discomfort and 87.0% experienced no more floaters, photopsia, or bubbles post-injection. Faricimab switching has anatomical efficacy but limited functional improvement in treatment-refractory AMD. Patient experiences of faricimab compared to previous injections were overall positive.

biology
Efficacy of Faricimab vs Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase 3 YOSEMITE/RHINE Trials

Marco Zarbin,David Tabano,Ayesha Ahmed,Manuel Amador,Allan Ding,Nancy Holekamp,Xiao-Yu Lu,Ivaylo Stoilov,Ming Yang

DOI: https://doi.org/10.1016/j.ophtha.2024.05.025

IF: 14.277

2024-06-10

Ophthalmology

Abstract:Purpose DRCR.net Protocol T data suggest the response to treatment among patients with diabetic macular edema (DME) may vary depending on baseline best-corrected visual acuity (BCVA). We evaluated the efficacy of faricimab 6 mg versus aflibercept 2 mg over 2 years in patients with DME enrolled in faricimab phase 3 trials with baseline Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA ≤20/50. Design YOSEMITE/RHINE were identically designed, multicenter, randomized, double-masked, active comparator–controlled, noninferiority trials. Participants Adults aged ≥18 years with center-involving macular edema secondary to type 1 or 2 diabetes. Methods Patients were randomized to faricimab every 8 weeks (Q8W), faricimab per a personalized treat-and-extend–based regimen (T&E), or aflibercept Q8W. Post hoc subgroup analyses were conducted using the intent-to-treat population with baseline BCVA ≤20/50 (ETDRS letters <69). Main Outcome Measures Changes in ETDRS BCVA and central subfield thickness (CST) from baseline to years 1 and 2 were compared between treatment arms using mixed-model repeated measures analyses. Results In YOSEMITE/RHINE, 220/217 patients in the faricimab Q8W; 220/219, faricimab T&E and 219/214, aflibercept Q8W arms had baseline BCVA ≤20/50. In both trials, mean change in ETDRS BCVA was comparable between treatments at years 1 and 2. In YOSEMITE, adjusted mean (95% CI) change from baseline in CST (μm) at year 1 was greater with faricimab Q8W (–232.8 [–243.5, –222.1]) and faricimab T&E (–217.4 [–227.9, –206.9]) versus aflibercept Q8W (–190.4 [–200.9, –179.8]; P <0.0001 and P =0.0004, respectively). The pattern was similar in RHINE: faricimab Q8W, –214.2 (–225.3, –203.1); faricimab T&E, –206.6 (–217.4, –195.7); aflibercept Q8W, –186.6 (–197.7, –175.5); P =0.0006 and P =0.0116 for faricimab arms versus aflibercept, respectively. In both trials, change from baseline in CST at year 2 was greater with faricimab Q8W versus aflibercept. Median time to first CST <325 μm and first absence of intraretinal fluid was shorter in the faricimab arms versus aflibercept, with fewer injections on average. Conclusions In patients with DME and baseline ETDRS BCVA ≤20/50, faricimab treatment resulted in comparable visual acuity, greater reduction in retinal thickness, and fewer injections compared with aflibercept over 2 years of treatment.

ophthalmology
Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema

Grace A. Borchert,Christine A. Kiire,Niamh M. Stone,Handan Akil,Theodora Gkika,M. Dominik Fischer,Kanmin Xue,Jasmina Cehajic-Kapetanovic,Robert E. MacLaren,Peter Charbel Issa,Susan M. Downes,Samantha R. De Silva

DOI: https://doi.org/10.1038/s41433-024-03364-y

IF: 4.4563

2024-10-12

Eye

Abstract:Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had previously shown a partial response to other anti-VEGF injections for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).

ophthalmology
Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema

Yoshinari Saima,Harumasa Yokota,Akifumi Kushiyama,Junya Hanaguri,Akira Ohno,Koyo Takase,Ruri Sugiyama,Kimimasa Muranaka,Satoru Yamagami,Taiji Nagaoka

DOI: https://doi.org/10.1038/s41598-024-63435-8

IF: 4.6

2024-06-15

Scientific Reports

Abstract:We assessed the short-term effects of switching from intravitreal aflibercept (IVA) to intravitreal faricimab (IVF) on ocular blood flow in patients with treatment-resistant diabetic macular edema (DME). The medical records of 15 patients with DME who had received IVA injection ≥ 3 months before were retrospectively reviewed. The best-corrected visual acuity, central macular thickness (CMT) on optical coherence tomography, and mean blur rate (MBR) of all disc areas on laser speckle flowgraphy were measured before, 1 week after, and 4 weeks after IVA and IVF, respectively. The changes in visual acuity showed no significant difference after switching from IVA to IVF (P = 0.732). The mean CMT decreased significantly during the follow-up period (both P < 0.001). MBR showed no significant difference during the follow-up period (P = 0.26). However, it decreased significantly 4 weeks after IVF (P = 0.01) compared with the baseline value, but not 4 weeks after IVA (P = 0.074). A significant association was observed between decreased MBR and decreased CMT in patients who received IVF (correlation coefficient: 0.501, P = 0.005) but not in those who received IVA (P = 0.735). Thus, IVF maintained ocular blood flow reduction, although no significant differences in visual acuity and CMT changes were observed compared to IVA.

multidisciplinary sciences
Greater reduction in hyperreflective foci with faricimab compared to aflibercept in patients with diabetic macular oedema

Esther von Schulthess,Andreas Maunz,Usha Chakravarthy,Nancy Holekamp,Rishi Singh,Katie Patel,Isabel Bachmeier,Siqing Yu,Kara Gibson,Jeffrey Willis,Carl Glittenberg,Sascha Fauser

DOI: https://doi.org/10.1111/aos.15824

2024-01-01

Acta Ophthalmologica

Abstract:Aims/Purpose: In diabetic macular oedema (DME), hyperreflective foci (HRF) may be a biomarker for disease severity and progression. This post hoc analysis aimed to test if faricimab, a dual‐action therapeutic inhibiting both vascular endothelial growth factor (VEGF)‐A and angiopoietin‐2 (Ang‐2), yields improved resolution of retinal HRF in DME compared to aflibercept. Methods: Phase 3 YOSEMITE/RHINE (NCT03622580/NCT03622593) spectral‐domain optical coherence tomography (SD‐OCT) volumes from 1527 DME patients were automatically segmented using a deep learning‐based HRF model trained with manually‐annotated B‐scans from phase 2 BOULEVARD (NCT02699450). Bright objects ≤50 μm in diameter were classified as retinal HRF. HRF volumes were assessed within the 1‐ and 3‐mm diameter Early Treatment Diabetic Retinopathy Study (ETDRS) rings, separated into inner and outer retina. Treatment groups were compared using a Mixed Model for Repeated Measures. Results: In the inner retina at 1 mm diameter, adjusted mean HRF volumes reduced more markedly from baseline to week 48 for faricimab every 8 weeks (Q8W; −118.29 pL) and faricimab treat&extend (T&E; −130.05 pL) than aflibercept Q8W (−58.67 pL; p = 0.0006 and p < 0.0001, for comparison of each faricimab arm vs aflibercept, averaged across all visits, respectively). In the inner retina at 3‐mm diameter, reductions from baseline to week 48 were − 406.76 pL (faricimab Q8W), −533.01 pL (faricimab T&E) and − 397.67 pL (aflibercept Q8W; p = 0.0142 and p = 0.0034, for comparison to aflibercept averaged across all visits, respectively). Similar, statistically significant results were obtained for the outer retina. Conclusions: Significantly greater retinal HRF volume reductions were observed with faricimab compared to aflibercept. Our findings of better resolution of the pathological manifestations of DME with faricimab support the therapeutic potential of dual Ang‐2/VEGF‐A inhibition.

ophthalmology
Durability and Efficacy of Faricimab in Treatment‐Resistant Retinal Edema Utilizing "Real‐World" Dosing Regimens

Shravan V. Savant,James T. Kwan,Fina Barouch,Jeffrey Chang,David J. Ramsey,Jeffrey Marx,Gregory Blaha,Kendra Klein-Mascia

DOI: https://doi.org/10.1155/2024/8583348

2024-11-06

Journal of Ophthalmology

Abstract:Purpose: To retrospectively analyze clinical outcomes of patients with "treatment‐resistant" neovascular age‐related macular degeneration or diabetic macular edema who were switched to intravitreal faricimab injections (IFIs) using a "real‐world" treat‐and‐extend (TAE) protocol. Methods: Seventy‐one eyes from 62 patients receiving antivascular endothelial growth factor injections were evaluated before and after switching to IFI. Demographic and clinical data were collected. Primary endpoints were treatment interval extension and presence of intraretinal or subretinal fluid on spectral‐domain optical coherence tomography (OCT) after switching to IFI. Secondary endpoints included best‐corrected visual acuity, average OCT central subfield thickness, and presence of a pigment epithelium detachment and pigment epithelium detachment height. Results: The average treatment interval after switching to IFI significantly increased from 37.6 ± 10.8 days to 45.2 ± 16.6 days (p = 0.0016). At the last follow‐up, 35% of eyes were able to achieve a fluid‐free status post‐IFI. A chi‐square test of independence validated this finding by showing a significant difference in the OCT findings trending towards less or no fluid on follow‐up (X 2 [3, N = 71] = 13.0705; p = 0.0003). The average central subfield thickness decreased from 327.2 ± 89.1 μm to 294.8 ± 86.5 μm (p = 0.0294). Best‐corrected visual acuity, intraocular pressure, pigment epithelium detachment presence, and height had no significant difference after switching to IFI. Conclusions: In "treatment‐resistant" patients receiving anti‐VEGF therapy for neovascular age‐related macular degeneration or diabetic macular edema, switching to IFI in a "real‐world" TAE protocol led to statistically significant improvements in treatment interval and retinal fluid on spectral domain OCT.

ophthalmology
One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Giuseppe Cancian,Arianna Paris,Lia Agliati,Angelica Rizzato,Michele Clerici,Giulio Volpe,Moreno Menghini,Gabriela Grimaldi

DOI: https://doi.org/10.1007/s40123-024-01036-4

2024-10-22

Ophthalmology and Therapy

Abstract:This study assessed the efficacy, durability, and safety of faricimab in patients with neovascular age-related macular degeneration (nAMD), previously treated with aflibercept or ranibizumab with unsatisfactory results.

ophthalmology
Real World One-Year Outcomes of Treatment Intensive Neovascular Age Related Macular Degeneration switched to Faricimab

Sing Yue Sim,Evangelia Chalkiadaki,Georgios Koutsocheras,Luke Nicholson,Sobha Sivaprasad,Praveen J Patel,Senthil Selvam,Bishwanath Pal,Pearse A Keane,Bhairavi Bhatia,Robin Hamilton,Moorfields Medical Retina Injection Service,Abison Logeswaran,Adnan Tufail,Avinash Gurbaxani,Catherine Egan,David Bessant,Dhanes Thomas,Heng Ling,Josef Huemer,Khadijah Basheer,Konstantinos Balaskas,Konstantinos Bouras,Lyndon Da Cruz,Mythili Natkunarajah,Narciss Okhravi,Niaz Islam,Parul Desai,Peter Addison,Ranjan Rajendram,Simona Esposti,Tjebo Heeren,Waheeda Rahman,Yasir Khan,Zoe Ockrim,Zubin Saihan

DOI: https://doi.org/10.1016/j.oret.2024.07.020

2024-07-29

Abstract:Purpose: To report one-year anatomical and functional real-world outcomes of treatment intensive neovascular age related macular degeneration (nAMD) patients switched to faricimab DESIGN: Retrospective multi-centre cohort study SUBJECTS: Consecutive nAMD patients on 4-weekly treatment interval with either ranibizumab or aflibercept 2mg in the last three visits within a treat and extend protocol (high treatment burden) prior to switch to faricimab at Moorfields Eye Hospital between 5/9/2022- 5/12/2022. Methods: Total number of nAMD patients switched to faricimab were identified from electronic medical records and those who met criteria of high treatment burden were included. Data collected included pre and post-switch visual acuity (VA), treatment intervals, length of follow-up, baseline macular morphology, changes in central subfield thickness (CST), macular fluid status and adverse events. Main outcome measures: VA, CST, presence of intraretinal fluid (IRF), subretinal fluid (SRF) and injection intervals over one-year following switch to faricimab. Results: A total of 130/ 286 (45.5%) eyes met inclusion criteria of being switched due to high treatment burden and 117 were included in analysis. Prior to switch to faricimab, these eyes received mean total number of injections of 33.4±19.6 over mean of 51.3±34.9 months. Mean number of injections in 12 months preceding switch was 10.1±1.6 and mean interval of the preceding three injections was 4.2±0.3 weeks. Mean VA, CST and percentage of patients with dry macula prior to switch were 66.0±11.9 ETDRS letters, 259.6±76.0μm and 18.3% respectively. Following switch, there was no statistical difference in mean VA after each visit and at 12 months. Mean CST statistically significantly reduced following the 3rd faricimab injection and at 12 months by 20.0μm (p=0.035) and 22.1μm (p=0.041) respectively. Mean treatment intervals increased to 6.9±2.3 weeks (p<0.005) at 12 months with 42.9% and 11.4% of patients being on ≥8 weekly and ≥12 weekly treatment intervals respectively. Conclusion: At 12 months, patients with nAMD with previous record of high treatment burden when switched to faricimab maintained visual acuities and improved anatomical outcomes on extended treatment intervals. Physician bias is inherent in these types of observational studies so a prospective randomised controlled trial is recommended to validate these findings.
Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab

Takahito Todoroki,Jun Takeuchi,Hikaru Ota,Yuyako Nakano,Ai Fujita Sajiki,Koichi Nakamura,Hiroki Kaneko,Koji M Nishiguchi

DOI: https://doi.org/10.1167/iovs.65.11.15

2024-09-03

Abstract:Purpose: To examine the changes in aqueous humor cytokine levels and clinical outcomes of switching from aflibercept to faricimab in eyes with neovascular age-related macular degeneration (nAMD). Methods: Fifty-four eyes of 54 patients with AMD undergoing treatment with aflibercept under a treat-and-extend (TAE) regimen were switched to faricimab and studied prospectively. Best-corrected visual acuity (BCVA; in logarithm of the minimum angle of resolution), central retinal thickness (CRT), central choroidal thickness (CCT), and exudative status were analyzed using optical coherence tomography. Aqueous humor was collected before and after the switch, and angiopoietin-2 (Ang-2), placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) A levels were measured. Results: After switching from aflibercept to faricimab, exudative changes improved in 28 eyes (52%), remained stable in eight eyes (15%), and worsened in 18 eyes (33%). BCVA changed from 0.27 ± 0.31 to 0.26 ± 0.29 (P = 0.46), CRT decreased from 306.2 ± 147.5 µm to 278.6 ± 100.4 µm (P = 0.11), and CCT changed from 189.5 ± 92.8 µm to 186.8 ± 93.9 µm (P = 0.21). VEGF-A levels were below the detection sensitivity in many cases throughout the pre- and post-switching periods. Ang-2 significantly decreased from 23.8 ± 23.5 pg/mL to 16.4 ± 21.9 pg/mL (P < 0.001), and PlGF significantly increased from 0.86 ± 0.85 pg/mL to 1.72 ± 1.39 pg/mL (P < 0.001). Conclusions: Switching from aflibercept to faricimab in patients with nAMD may not only suppress VEGF-A but also Ang-2 and reduce exudative changes.
Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration

Lisa Toto,Federico Formenti,Maria Ludovica Ruggeri,Alberto Quarta,Anna Romano,Chiara De Nicola,Luca Belloni Baroni,Annamaria Porreca,Marta Di Nicola,Rodolfo Mastropasqua

DOI: https://doi.org/10.1159/000540194

Abstract:Introduction: The aim of the study was to evaluate functional and anatomical changes in patients with neovascular age-related macular degeneration (nAMD) treated with a loading dose of faricimab intravitreal injections (IVIs). Methods: Eighteen eyes of 18 patients with active macular neovascularization and nAMD were enrolled at the Ophthalmology Clinic of University G. D'Annunzio, Chieti-Pescara, Italy. All patients were scheduled for faricimab IVI as per label. Enrolled patients underwent complete ophthalmic evaluation, including optical coherence tomography, fluorescein angiography, and indocyanine green angiography. All measurements were evaluated at baseline (T0) and then monthly up to week 20 (T4). Main outcome measures were changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), pigment epithelial detachments (PEDs) presence and maximum height (PED-MH), intraretinal fluid (IRF) presence, subfoveal subretinal fluid (SSRF) presence and thickness. Results: BCVA improved and CMT reduced significantly during follow-up (p < 0.001). In addition, SFCT decreased significantly (p = 0.031). Between T0 and T4, SSRF presence reduced from 55.6 to 16.7% (p = 0.045); IRF presence changed from 50 to 22.2%, respectively (p = 0.074). PED-MH was reduced in 58.8% of patients at T4. At week 20, 72.3% of patients were in the q12/q16 interval. Conclusion: Faricimab showed efficacy in the treatment of naïve nAMD patients with an improvement of anatomical and functional parameters and a treatment interval after the loading phase equal or greater than 12 weeks in the majority of patients.
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes

Westenskow, Peter D.

DOI: https://doi.org/10.1007/s00417-024-06531-9

2024-06-08

Graefe s Archive for Clinical and Experimental Ophthalmology

Abstract:Intravitreal anti–vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); however, vision gains and anatomical improvements are not sustained over longer periods of treatment, suggesting other relevant targets may be needed to optimize treatments. Additionally, frequent intravitreal injections can prove a burden for patients and caregivers. Angiopoietin-2 (Ang-2) has been explored as an additional therapeutic target, due to the involvement of Ang-2 in DME and nAMD pathogenesis. Recent evidence supports the hypothesis that targeting both VEGF and Ang-2 may improve clinical outcomes in DME and nAMD compared with targeting VEGF alone by enhancing vascular stability, resulting in reduced macular leakage, prevention of neovascularization, and diminished inflammation. Faricimab, a novel bispecific antibody that targets VEGF-A and Ang-2, has been evaluated in clinical trials for DME (YOSEMITE/RHINE) and nAMD (TENAYA/LUCERNE). These trials evaluated faricimab against the anti-VEGFA/B and anti–placental growth factor fusion protein aflibercept, both administered by intravitreal injection. In addition to faricimab efficacy, safety, and pharmacokinetics, durability was evaluated during the trials using a treat-and-extend regimen. At 1 year, faricimab demonstrated non-inferior vision gains versus aflibercept across YOSEMITE/RHINE and TENAYA/LUCERNE. In YOSEMITE/RHINE, faricimab improved anatomic parameters versus aflibercept. Reduction of central subfield thickness (CST), and absence of both DME and intraretinal fluid were greater in faricimab- versus aflibercept-treated eyes. In TENAYA/LUCERNE, CST reductions were greater for faricimab than aflibercept at the end of the head-to-head phase (0–12 weeks), and were comparable with aflibercept at year 1, but with less frequent dosing. CST and vision gains were maintained during year 2 of both YOSEMITE/RHINE and TENAYA/LUCERNE. These findings suggest that dual Ang-2/VEGF-A pathway inhibition may result in greater disease control versus anti-VEGF alone, potentially addressing the unmet needs and reducing treatment burden, and improving real-world outcomes and compliance in retinal vascular diseases. Long-term extension studies (RHONE-X, AVONELLE-X) are ongoing. Current evidence suggests that dual inhibition with faricimab heralds the beginning of multitargeted treatment strategies inhibiting multiple, independent components of retinal pathology, with faricimab providing opportunities to reduce treatment burden and improve outcomes compared with anti-VEGF monotherapy.

ophthalmology
Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population

Farah N I Ibrahim,Kelvin Y C Teo,Tien-En Tan,Hiok Hong Chan,Priya R Chandrasekaran,Shu-Yen Lee,Anna C S Tan,Ranjana Mathur,Choi Mun Chan,Shaun S Sim,Gavin Siew Wei Tan,Ian Y S Yeo,Chui Ming Gemmy Cheung

DOI: https://doi.org/10.3389/fopht.2023.1346322

2024-01-11

Abstract:Purpose: To describe the early experiences of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) whose treatment was switched to faricimab from other anti-vascular endothelial growth factor (VEGF) agents. Methods: This is a prospective cohort of eyes with nAMD and PCV that were previously treated with anti-VEGF agents other than faricimab. We evaluated visual acuity (VA), central subfield thickness (CST), macular volume (MV), pigment epithelial detachment (PED) height, and choroidal thickness (CT) after one administration of faricimab. Where present, fluid was further evaluated according to intraretinal fluid (IRF), subretinal fluid (SRF), or within PED. Results: Seventy-one eyes from 71 patients were included (45.07% PCV and 54.93% typical nAMD). The mean [standard deviation (± SD)] VA, CST, and MV improved from 0.50 logMAR (± 0.27 logMAR) to 0.46 logMAR (± 0.27 logMAR) (p = 0.20), 383.35 µm (± 111.24 µm) to 322.46 µm (± 103.89 µm (p < 0.01), and 9.40 mm3 (± 1.52 mm3) to 8.75 mm3 (± 1.17 mm3) (p < 0.01) from switch to post switch visit, respectively. The CT reduced from 167 µm (± 151 µm) to 149 µm (± 113 µm) (p < 0.01). There was also a significant reduction in the maximum PED height between visits [302.66 µm (± 217.97 µm)] and the post switch visit [236.66 µm (± 189.05 µm); p < 0.01]. This difference was greater in PEDs that were predominantly serous in nature. In the eyes with typical nAMD (n = 39), improvements were significant for CST, MV, CT, and PED. In the eyes with PCV (n = 32), only reductions in CT were statistically significant, while VA, CST, MV, and PED only showed numerically smaller improvements. One patient developed mild vitritis without vasculitis, which resolved with topical steroids with no sequelae. Conclusions: In our case series of Asian nAMD patients, switching to faricimab was associated with a stable VA and meaningful anatomical improvements, particularly with typical nAMD subtypes.
Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)

Ermete Giancipoli,Antonella Guglielmi,Anna Valeria Bux,Giulia Maria Emilia Clima,Francesco Pignatelli,Francesco Boscia,Pasquale Viggiano,Giacomo Boscia,Francesca Fortunato,Gianluca Besozzi,Alfredo Niro,Stefano Dore,Cristiana Iaculli

DOI: https://doi.org/10.1007/s40123-024-00980-5

2024-06-06

Ophthalmology and Therapy

Abstract:The aims of this work were to evaluate the real-world efficacy and safety of a loading dose of intravitreal faricimab in eyes with active neovascular age-related macular degeneration (n-AMD) or diabetic macular edema (DME) and to analyze the treatment outcome in relation to specific biomarkers.

ophthalmology
Changes in Ocular Blood Flow After Intravitreal Injection for Diabetic Macular Edema Between Aflibercept and Faricimab

Takahiro Mizukami,Saya Mizumoto,Takuya Ishibashi,Satoru Ueno,Takayo Toyonishi,Kuniko Tachibana,Soichiro Mishima,Yoshikazu Shimomura

DOI: https://doi.org/10.2147/OPTH.S476307

2024-08-27

Abstract:Purpose: In this study, we aimed to evaluate and compare the effects of intravitreal aflibercept (IVA) and intravitreal faricimab (IVF) injections on the blood flow of retinal vessels in the peripapillary region and optic nerve head (ONH) in eyes with diabetic macular edema (DME) using laser speckle flowgraphy (LSFG). Patients and methods: This study included 20 eyes of 18 patients treated with IVA and 15 eyes of 11 patients treated with IVF for DME. The mean blur rate (MBR) of the ONH and retinal artery and vein of the peripapillary region were measured using LSFG at baseline and 1 month after injection. Central retinal thickness (CRT) and best-corrected visual acuity (BCVA) were measured for all patients. Results: CRT decreased significantly in both IVA-treated (p = 0.0003) and IVF-treated groups (p = 0.0004). Some of the MBR-related parameters of the ONH, such as MBR of all areas (MA), MBR of vascular areas (MV), and MBR of tissue areas (MT), decreased significantly 1 month after IVA and IVF compared to baseline values (MA of IVA, p < 0.0001; MT of IVA, p = 0.0220; MA of IVF, p = 0.0002; MT of IVF, p = 0.0461). MBR of the retinal artery (MBR-A) and vein (MBR-V) also decreased significantly 1 month after IVA and IVF compared with baseline values (MBR-A of IVA, p = 0.0002; MBR-V of IVA, p = 0.0010; MBR-A of IVF, p = 0.0368). No significant difference in ocular perfusion was observed between the IVA-treated and IVF-treated groups. Conclusion: Intravitreal injection led to a reduction in ocular blood flow in both retinal peripapillary vessels and the ONH in both IVA-treated and IVF-treated groups. No significant difference was observed in MBR reduction between the IVA-treated and IVF-treated groups. Our findings warrant further long-term investigations to reveal differences between aflibercept and faricimab.
Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis

Daniel Samacá-Samacá,Claudia Hernández-Castillo,Laura Prieto-Pinto,Francisco Rodríguez,Carolina Sardi,Hugo Ocampo,Joshua Kock,Fabián Hernández

DOI: https://doi.org/10.1136/bmjophth-2024-001702

2024-07-23

Abstract:Objective: To evaluate the efficacy and safety of faricimab compared with other anti-vascular endothelial growth factor (anti-VEGF) agents in treating neovascular age-related macular degeneration (nAMD) patients. Methods and analysis: A systematic review (SR) was conducted up to January 2023. Network meta-analyses (NMA) were performed, including sensitivity and subgroup analyses for naïve population. Outcomes included changes in visual acuity (Early Treatment of Diabetic Retinopathy Study [ETDRS] letters), anatomical changes, frequency of injections and adverse events. The Cochrane Collaboration guidelines and the Confidence in Network Meta-Analysis framework were used for the SR and the certainty of evidence, respectively. Results: From 4128 identified records through electronic databases and complementary searches, 63 randomised controlled trials (RCTs) met the eligibility criteria, with 42 included in the NMA. Faricimab showed a significant reduction in the number of annual injections compared with most fixed and flexible anti-VEGF treatment regimens, while showing no statistically significant differences in visual acuity through ETDRS letter gain, demonstrating a comparable efficacy. Retinal thickness results showed comparable efficacy to other anti-VEGF agents, and inferior only to brolucizumab. Results also showed that more patients treated with faricimab were free from post-treatment retinal fluid compared with aflibercept every 8 weeks, and both ranibizumab and bevacizumab, in the fixed and pro re nata (PRN) assessed schedules. Faricimab showed a comparable safety profile regarding the risk of ocular adverse events and serious ocular adverse events (SOAE), except for the comparison with brolucizumab quarterly, in which faricimab showed a significant reduction for SOAE risk. Conclusion: Faricimab showed a comparable clinical benefit in efficacy and safety outcomes, with a reduction in annual injections compared with fixed and flexible anti-VEGF drug regimens, representing a valuable treatment option for nAMD patients. Prospero registration number: CRD42023394226.

Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration

Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema

Comparative effect of intravitreal faricimab versus aflibercept in a patient with diabetic macular oedema

Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration

Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration

Efficacy of Faricimab vs Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase 3 YOSEMITE/RHINE Trials

Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema

Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema

Greater reduction in hyperreflective foci with faricimab compared to aflibercept in patients with diabetic macular oedema

Durability and Efficacy of Faricimab in Treatment‐Resistant Retinal Edema Utilizing "Real‐World" Dosing Regimens

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Real World One-Year Outcomes of Treatment Intensive Neovascular Age Related Macular Degeneration switched to Faricimab

Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab

Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration

Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes

Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population

Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)

Changes in Ocular Blood Flow After Intravitreal Injection for Diabetic Macular Edema Between Aflibercept and Faricimab

Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis